NCT02117661View on ClinicalTrials.gov

Carnitine for the Treatment of Atherosclerosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

May 31, 2019

Conditions
Metabolic Syndrome
Interventions
DIETARY_SUPPLEMENT

L-carnitine capsules

Oral

DIETARY_SUPPLEMENT

Cellulose capsules

oral

Trial Locations (2)

K7L 3N6

Queen's University, Cardiovascular Imaging Network at Queen's (CINQ), Kingston General Hospital, Kingston

N6G 2V2

Robarts Institute, Stroke Prevention & Atherosclerosis Research Centre (SPARC), London

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

collaborator

Queen's University

OTHER

lead

Dr. Amer Johri

OTHER

NCT02117661 - Carnitine for the Treatment of Atherosclerosis. | Biotech Hunter | Biotech Hunter